INGELHEIM, Germany - Monday, June 2nd 2014 [ME NewsWire]

    Non-small cell lung cancer (NSCLC) patients with the del19 EGFR mutation lived a median of more than one year longer if they started treatment with afatinib rather than standard chemotherapy1
    Afatinib is the first treatment to demonstrate an overall survival benefit for patients with specific types of EGFR mutation-positive NSCLC1

2014 ASCO Annual Meeting

(BUSINESS WIRE)-- For Ex-US and Ex-UK Media only

Boehringer Ingelheim today announced results of the pre-specified individual, as well as the exploratory combined, analyses of two Phase III trials (LUX-Lung 3 and LUX-Lung 6). These data, to be presented at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO), demonstrated for the first time that patients with NSCLC with the most common epidermal growth factor receptor (EGFR) mutation (exon 19 deletions; del19) lived more than one year longer if treated with first-line afatinib compared to chemotherapy.1

Del19 is the most common type of EGFR mutation. It accounts for 50% of all EGFR mutations. The prevalence of EGFR mutations is approximately 40% among Asian patients and 10-15% among Caucasian patients with lung adenocarcinoma.2,3,4 For patients with the del19 mutation afatinib prolonged survival by 12.2 months versus chemotherapy in the LUX-Lung 3 trial, and 13.0 months versus chemotherapy in the LUX-Lung 6 trial. 1

Principal investigator Professor James Chih-Hsin Yang, M.D., Ph.D., National Taiwan University Hospital in Taiwan commented: “NSCLC patients with the del19 EGFR mutation lived a median of more than one year longer if they started treatment with afatinib rather than standard chemotherapy. Afatinib is the first treatment to demonstrate an overall survival benefit for these patients. LUX-Lung 3 and LUX-Lung 6 represent a potential change in the use of personalised medicine for treating patients with NSCLC. I think that these data support afatinib as the treatment of choice for patients with the del19 mutation.”

Afatinib: approved and investigational indications

Afatinib (GIOTRIF® / GILOTRIF®) is indicated for the treatment of distinct types of EGFR mutation-positive NSCLC. Afatinib is approved in a number of markets, including the EU, Japan, Taiwan and Canada under the brand name GIOTRIF® and in the U.S. under the brand name GILOTRIF®. It is under regulatory review in other countries. Phase III trials in squamous head and neck cancer (HNSCC) and trials in other tumour types are ongoing.

Please click on the link below for ‘Notes to Editors’ and ‘References’:

www.boehringer-ingelheim.com

Contacts

Boehringer Ingelheim

Corporate Communications

Media + PR

Duncan Cantor

Phone: +44 (1344) 74-1235

Fax: +44 (7785) 324536

Email: press@boehringer-ingelheim.com

More information

www.boehringer-ingelheim.com

Permalink: http://www.me-newswire.net/news/11190/en